EF-2 peptide

EF-2 peptide is a tumor-specific synthetic peptide vaccine developed by the National Cancer Institute (NCI) for the treatment of pediatric sarcomas, primarily Ewing sarcoma. It is derived from the breakpoint junction of the EWS-FLI1 fusion protein, which results from the t(11;22)(q24;q12) chromosomal translocation characteristic of approximately 85-90% of Ewing sarcoma cases. The peptide is designed to be loaded onto autologous antigen-presenting cells (APCs) to induce a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the fusion protein. In clinical trials, such as the Phase 2 pilot study NCI-97-C-0052, EF-2 is administered as part of a vaccination protocol that may include other fusion-specific peptides (like PXFK for alveolar rhabdomyosarcoma) and systemic cytokines like interleukin-2 (IL-2) to enhance immune activation and T-cell expansion.

Other names

EF-2 peptideEF2 peptideEF 2 peptideEWS-FLI1 fusion junction peptide 2EWS-FLI-1 fusion junction peptide 2EWS-FLI 1 fusion junction peptide 2EWS-FLI1 peptideEWS-FLI-1 peptideEWS-FLI 1 peptide